Highlighting the need for early detection and novel CRC therapies, it examines HBD-1’s ability to inhibit the mTOR pathway, a key regulator of cell growth, positioning defensin-based treatments as a promising approach with evidence for suppressing cancer cell proliferation and tumor growth. This evidence concerns the gene MTOR and neoplasm.